Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research25

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research25

FiltersClear all

Status

Recruiting6
Active, not recruiting17
Completed2

Study type

Interventional25

Phase

Phase 325
Phase 219
Not applicable8
Phase 1/24
Phase 2/34
Phase 11

Investigator

Hani Lamie Ashamalla7
Eleni Andreopoulou3
Alexander Ja-Ho Chou2
Silvia Chiara Formenti2
Nitya Gulati2

Department

Radiation Oncology10
Medicine7
Pediatrics5
Neurology1
Obstetrics and Gynecology1

Show all 6

Condition

Breast Neoplasms7
Prostatic Neoplasms3
Brain Neoplasms2
Burkitt Lymphoma2
Carcinoma, Non-Small-Cell Lung2

Intervention type

Radiation25
Drug288
Biological54
Other53
Procedure37
Device11

Sponsor type

NIH8
Other academic7
Industry4
Cooperative group4
WCM (investigator-initiated)2

Start date

Has results posted4

Phase 3×Radiation×Clear all

Showing 1–20 of 25 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

FiltersClear all

Status

Recruiting6
Active, not recruiting17
Completed2

Study type

Interventional25

Phase

Phase 325
Phase 219
Not applicable8
Phase 1/24
Phase 2/34
Phase 11

Investigator

Hani Lamie Ashamalla7
Eleni Andreopoulou3
Alexander Ja-Ho Chou2
Silvia Chiara Formenti2
Nitya Gulati2

Department

Radiation Oncology10
Medicine7
Pediatrics5
Neurology1
Obstetrics and Gynecology1

Show all 6

Condition

Breast Neoplasms7
Prostatic Neoplasms3
Brain Neoplasms2
Burkitt Lymphoma2
Carcinoma, Non-Small-Cell Lung2

Intervention type

Radiation25
Drug288
Biological54
Other53
Procedure37
Device11

Sponsor type

NIH8
Other academic7
Industry4
Cooperative group4
WCM (investigator-initiated)2

Start date

Has results posted4

Phase 3×Radiation×Clear all

Showing 1–20 of 25 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Show all 14

Show fewer

Doru Paul1
Douglas S Scherr1
Evelyn Cantillo1
Howard Alan Fine1
Jaclyn Rosenzweig1
Jia Ruan1
Manish A Shah1
Raymond Luke1
Scott T. Tagawa1

Show fewer

Urology1

Show all 26

Show fewer

Lung Neoplasms2
Parkinson Disease 4, Autosomal Dominant Lewy Body2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma2
Adenocarcinoma Of Esophagus1
Breast Carcinoma In Situ1
Carcinoma, Renal Cell1
Carcinosarcoma1
Down Syndrome1
Esophageal Squamous Cell Carcinoma1
Glioblastoma1
Head and Neck Neoplasms1
Hodgkin Disease1
Leukemia, Biphenotypic, Acute1
Melanoma1
Neoplasm Metastasis1
Oropharyngeal Neoplasms1
Pancreatic Neoplasms1
Rhabdomyosarcoma1
Rhabdomyosarcoma, Alveolar1
Rhabdomyosarcoma, Embryonal1
Triple Negative Breast Neoplasms1

Combination product

Intervention: Procedure: Axillary Lymph Node Dissection (ALND) · Radiation: Nodal Radiation Therapy · Radiation: Axillary Radiation Therapy
Dates: Feb 2014 – Jan 2031 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Stage II Breast CancerStage IIIA Breast Cancer

Active, not recruitingInterventional · Phase 3NCT02954874 ↗

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Eleni AndreopoulouPI

Intervention: Procedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy
Dates: Jan 2017 – Aug 2026
Sponsor: Southwest Oncology Group

Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more

Active, not recruitingInterventional · Phase 3NCT03488693 ↗

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Hani Lamie AshamallaPI

Intervention: Radiation: Radiation · Other: No Radiation
Dates: Oct 2018 – Sep 2027 (est.)
Sponsor: Canadian Cancer Trials Group

Breast Cancer

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

Active, not recruitingInterventional · Phase 3NCT03725059 ↗

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Eleni AndreopoulouPI

Intervention: Biological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: Surgery
Dates: Dec 2018 – Jan 2031 (est.)
Sponsor: Merck & Co., Inc.

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT03765918 ↗

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Doru PaulPI

Intervention: Biological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2
Dates: Dec 2018 – Jul 2024· Results posted
Sponsor: Merck Sharp & Dohme Corp

Head and Neck Neoplasms

Active, not recruitingInterventional · Phase 3NCT03811015 ↗

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Hani Lamie AshamallaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission Tomography
Dates: Aug 2019 – Jan 2030 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Active, not recruitingInterventional · Phase 3NCT03907488 ↗

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Jia RuanPI

Intervention: Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine Sulfate
Dates: Aug 2019 – Mar 2024· Results posted
Sponsor: Southwest Oncology Group

Ann Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more

Active, not recruitingInterventional · Phase 3NCT03914625 ↗

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Alexander Ja-Ho ChouPI

Intervention: Drug: Asparaginase Erwinia chrysanthemi · Biological: Blinatumomab · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Drug: Leucovorin Calcium · Drug: Mercaptopurine · Drug: Mercaptopurine Oral Suspension · Drug: Methotrexate · Drug: Pegaspargase · Drug: Prednisolone · Drug: Prednisone · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine Sulfate
Dates: Jul 2019 – Sep 2027 (est.)
Sponsor: Children's Oncology Group

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome

RecruitingInterventional · Phase 3NCT03959085 ↗

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Jaclyn RosenzweigPI

Intervention: Procedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Drug: Calaspargase Pegol · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Biological: Inotuzumab Ozogamicin · Drug: Leucovorin Calcium · Procedure: Magnetic Resonance Imaging · Drug: Mercaptopurine · Drug: Methotrexate · Drug: Pegaspargase · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine Sulfate
Dates: Oct 2019 – Mar 2032 (est.)
Sponsor: Children's Oncology Group

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaCentral Nervous System Leukemia+2 more

Active, not recruitingInterventional · Phase 3NCT04175210 ↗

Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)

Silvia Chiara FormentiPI

Intervention: Radiation: Radiation therapy - 3 weeks · Radiation: Radiation therapy - 2 weeks
Dates: Nov 2019 – Jul 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT04214067 ↗

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Evelyn CantilloPI

Intervention: Procedure: Biospecimen Collection · Radiation: Brachytherapy · Procedure: Computed Tomography · Radiation: External Beam Radiation Therapy · Procedure: Magnetic Resonance Imaging · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Procedure: X-Ray Imaging
Dates: Apr 2020 – Dec 2025
Sponsor: NRG Oncology

Endometrial Endometrioid AdenocarcinomaStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Active, not recruitingInterventional · Phase 3NCT04214262 ↗

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Hani Lamie AshamallaPI

Intervention: Drug: Atezolizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy
Dates: Aug 2020 – Aug 2024· Results posted
Sponsor: SWOG Cancer Research Network

Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8

Active, not recruitingInterventional · Phase 3NCT04513717 ↗

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Scott T. TagawaPI

Intervention: Drug: Apalutamide · Drug: Bicalutamide · Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Buserelin · Procedure: Computed Tomography · Drug: Degarelix · Drug: Flutamide · Drug: Goserelin · Drug: Histrelin · Drug: Leuprolide · Procedure: Magnetic Resonance Elastography · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Relugolix · Drug: Triptorelin
Dates: Jan 2021 – Dec 2033 (est.)
Sponsor: NRG Oncology

Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

Active, not recruitingInterventional · Phase 3NCT04759586 ↗

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Nitya GulatiPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Doxorubicin Hydrochloride · Procedure: Echocardiography Test · Drug: Etoposide Phosphate · Biological: Filgrastim · Procedure: Lumbar Puncture · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Radiation: Radiation Therapy · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Drug: Vincristine Sulfate
Dates: Oct 2021 – Jun 2027 (est.)
Sponsor: Children's Oncology Group

Primary Mediastinal Large B-Cell Lymphoma

Active, not recruitingInterventional · Phase 3NCT04994132 ↗

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Procedure: Computed Tomography · Drug: Cyclophosphamide · Biological: Dactinomycin · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Radiation: Radiation Therapy · Drug: Vincristine Sulfate · Drug: Vinorelbine Tartrate · Procedure: X-Ray Imaging
Dates: Sep 2021 – Jun 2026
Sponsor: Children's Oncology Group

Alveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal Rhabdomyosarcoma+5 more

Active, not recruitingInterventional · Phase 3NCT05050084 ↗

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Hani Lamie AshamallaPI

Intervention: Drug: Bicalutamide · Drug: Buserelin · Drug: Darolutamide · Drug: Degarelix · Drug: Flutamide · Drug: Goserelin · Drug: Histrelin · Drug: Leuprolide · Radiation: Radiation Therapy · Drug: Relugolix · Drug: Triptorelin
Dates: Dec 2021 – Nov 2026 (est.)
Sponsor: NRG Oncology

Prostate Adenocarcinoma

Active, not recruitingInterventional · Phase 3NCT05438212 ↗

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases

Hani Lamie AshamallaPI

Intervention: Procedure: Brain Surgery · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Radiosurgery
Dates: Oct 2022 – Mar 2027 (est.)
Sponsor: NRG Oncology

Metastatic Malignant Neoplasm in the Brain

RecruitingInterventional · Phase 3NCT05675410 ↗

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Nitya GulatiPI

Intervention: Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Drug: Etoposide Phosphate · Other: Fludeoxyglucose F-18 · Radiation: Involved-site Radiation Therapy · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Drug: Procarbazine Hydrochloride · Other: Questionnaire Administration · Drug: Vinblastine Sulfate · Drug: Vincristine Sulfate
Dates: May 2023 – Apr 2031 (est.)
Sponsor: Children's Oncology Group

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

RecruitingInterventional · Phase 3NCT05946213 ↗

The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer

Hani Lamie AshamallaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Radiation: External Beam Radiation Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy
Dates: Dec 2023 – Mar 2036 (est.)
Sponsor: NRG Oncology

Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

‹ Prev1 2 Next ›